Slingshot members are tracking this event:

Phase 3 PALISADE trial of AR101 for Peanut Allergy to be completed Q4 2017

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
AIMT Community voting in process

Additional Information

Additional Relevant Details Aimmune expects to complete enrollment in PALISADE in the second half of 2016 and complete the trial in the second half of 2017
Additional Relevant Details Update on June 20 2017: "Once the trial is completed, we will also be able to examine in detail the links between baseline characteristics and outcomes, from both an efficacy and a safety perspective.”
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3 Trial, Ar101, Peanut Allergy, Palisade